Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Analyst Comment

Gubra indgår partnerskab med Abbvie på GUBamy

Gubra

Selskabet meddeler her til morgen at de har indgået partneraftale på GUBamy (Amylin peptide) som er i Fase 1a, og hvor vi venter de første data fra fase 1b i april 2025. Gubra modtager USD 350 mio. i upfront betaling samt USD 1,875 mia i udviklings- og kommercialiseringsomkostninger samt royalties fra globalt salg.

Abbvie er det 6. største farmaselskab globalt og partneraftalen med Gubra er deres indtog i "Obesity" markedet.

Aftalen venter godkendelse af relevante myndigheder.

Selskabet præsentere partnerskabsaftalen i dag kl 10:00. Læs hele meddelelsen og tilmeld dig til dagens event her:Gubra partnerskabsaftale med Abbvie

Disclaimer: HC Andersen Capital modtager betaling fra Gubra på en Digital IR/Corporate Visibility aftale./Claus Thestrup 03.03.2025 kl 08:35.

Gubra is a pharmaceutical company. The company's operations are focused on the early stages of drug development. They primarily conduct research and development in the area of metabolic and fibrotic diseases. The company's product portfolio includes several brands and drugs, and the operations are conducted on a global level, with the largest presence in North America and the Nordic region. The headquarters are located in Hørsholm, Denmark.

Read more on company page
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.